Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance
about
MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activityHarnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinomaThe crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53Cancer/testis antigens, gametogenesis and cancerLocalization of TRAIL/TRAILR in fetal pancreasGradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significanceThe regulation of non-coding RNA expression in the liver of mice fed DDC.MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase.Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasisIdentification of miR-145 targets through an integrated omics analysis.Intracellular signaling and hepatocellular carcinoma.Up-regulated oncoprotein P28GANK correlates with proliferation and poor prognosis of human glioma.Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China.Gene therapy strategies for hepatocellular carcinoma.Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells.Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.Coping with stress: multiple ways to activate p53.Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?The impact of hypoxia in hepatocellular carcinoma metastasis.Expression of the oncoprotein gankyrin and phosphorylated retinoblastoma protein in human testis and testicular germ cell tumor.Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways.Overexpression of a new gene P28GANK confers multidrug resistance of gastric cancer cells.Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin.p28GANK inhibits endoplasmic reticulum stress-induced cell death via enhancement of the endoplasmic reticulum adaptive capacity.Gene and protein expressions of p28GANK in rat with liver regeneration.The role of p28GANK in rat oval cells activation and proliferation.Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma.Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.Minority stress and leukocyte gene expression in sexual minority men living with treated HIV infection.
P2860
Q24338637-B9AD2EA3-8B06-41CB-A9F8-5C6B81B76FD2Q27488744-97BE511A-1421-456F-AEBF-5763F919BB0EQ27642398-78E05D2D-FD22-4CAE-91D7-D2BDFF9F1A6DQ29616129-42343C4F-737B-467B-9303-CBC5C148B8ACQ30881749-9B400F35-D211-474F-A37A-40D52BB0DD6BQ33851157-B16696CF-39B5-4EF0-86AF-3F29162CCAD7Q33911063-A19C5A4D-84A5-4816-AF46-C08FD6BAE7D2Q34264405-D201FF95-C05A-4808-BF9F-63F0F586B712Q34502804-5DECB54B-DE48-4AA4-A394-091C05167ED0Q34619226-83F3C1A0-2D9D-40A1-895B-D5C5BBAF31FBQ35153915-7A9F7CDF-2CAD-40F3-AAB6-94970BF021D3Q35155627-8837673F-F899-4391-B654-C0503FD2DB7DQ35586439-46D44CD0-FBC3-4BB9-B75D-C840AE5EBAC2Q36235734-E7D277FF-38DA-4BCD-90FF-EDF7CD91965CQ36308812-24285171-5EC2-4D8A-AB10-8EA01888A8A8Q36457829-9D95ECDA-3005-4E77-9BA6-33F5F13D3AA1Q36502549-54A8999D-0F9C-492E-9AE2-69F78EB0870EQ36572527-A6267B19-F612-4668-9FCD-ECD7691FD896Q36745375-6819134E-7A08-4C62-AC93-AAAB359711B6Q36863127-8D8032BA-C56D-4266-B93D-A5347B5B335FQ37961864-6345B84D-BAF9-48A0-B8A2-82D5833E7683Q38162804-1900CD12-8759-4BD3-A844-7925AC06DFDCQ38991575-BC2051BC-78AD-4E0B-A509-B8B05B2B2780Q39043145-3BA1C5E8-2D06-4645-A7BA-02509D9ED445Q39240990-DB6CA572-6438-4BC9-A3FE-17F6C8B36CE6Q39511329-80493663-50D6-4AF7-9AB1-8B7943A0A590Q39604806-BBEC6840-594C-4D66-81D3-71EA1F210080Q39880807-0C3B69AC-B1AC-41ED-A215-0C6780F4E2EFQ40030453-8521E112-227A-49BD-8599-10B8D46C910AQ41982097-EDC70E6D-F3B4-4F47-ABD8-BEC60CC0AD01Q42548703-7B46BCB0-08C3-4696-9A72-5EC71D04338FQ42834062-40150070-D8F1-46AF-82C8-314DAD5BCA26Q43159668-3243094F-467C-4E92-91EE-30E34AEB16B7Q46920600-4C0BAE09-3800-4A58-A60D-CC62689DBD8FQ47661011-C05C5431-EEB9-4287-A2B4-8ECA02977E88Q53090136-A5294E1E-2B00-4AF1-9AC8-D2BF8125D3BDQ54254509-716F7EAB-B503-4E51-9689-831E91F07933
P2860
Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Overexpression of p28/gankyrin ...... and its clinical significance
@ast
Overexpression of p28/gankyrin ...... and its clinical significance
@en
Overexpression of p28/gankyrin ...... and its clinical significance
@nl
type
label
Overexpression of p28/gankyrin ...... and its clinical significance
@ast
Overexpression of p28/gankyrin ...... and its clinical significance
@en
Overexpression of p28/gankyrin ...... and its clinical significance
@nl
prefLabel
Overexpression of p28/gankyrin ...... and its clinical significance
@ast
Overexpression of p28/gankyrin ...... and its clinical significance
@en
Overexpression of p28/gankyrin ...... and its clinical significance
@nl
P2093
P2860
P356
P1476
Overexpression of p28/gankyrin ...... and its clinical significance
@en
P2093
Hong-Yang Wang
Hui-Fang Cao
Meng-Chao Wu
Shu-Qin Liu
Xiao-Yong Fu
P2860
P304
P356
10.3748/WJG.V8.I4.638
P407
P577
2002-08-01T00:00:00Z